1. Home
  2. FRMI vs BLCO Comparison

FRMI vs BLCO Comparison

Compare FRMI & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FRMI

Fermi Inc.

N/A

Current Price

$10.14

Market Cap

6.0B

Sector

Real Estate

ML Signal

N/A

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

HOLD

Current Price

$18.40

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRMI
BLCO
Founded
2025
1853
Country
United States
Canada
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Ophthalmic Goods
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.0B
6.0B
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
FRMI
BLCO
Price
$10.14
$18.40
Analyst Decision
Strong Buy
Buy
Analyst Count
8
12
Target Price
$29.50
$18.55
AVG Volume (30 Days)
6.4M
437.5K
Earning Date
01-01-0001
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$5,101,000,000.00
Revenue This Year
N/A
$7.45
Revenue Next Year
$3,129.57
$5.49
P/E Ratio
N/A
N/A
Revenue Growth
N/A
6.47
52 Week Low
$7.18
$10.45
52 Week High
$32.39
$18.92

Technical Indicators

Market Signals
Indicator
FRMI
BLCO
Relative Strength Index (RSI) 52.39 64.59
Support Level $8.69 $16.35
Resistance Level $10.57 N/A
Average True Range (ATR) 1.03 0.63
MACD 0.18 0.11
Stochastic Oscillator 47.10 78.80

Price Performance

Historical Comparison
FRMI
BLCO

About FRMI Fermi Inc.

Fermi Inc is an energy and hyperscaler development company purpose-built for the AI era. Its Project Matador, a multi-gigawatt energy and data center development campus designed to support the accelerating needs of to-be-built AI infrastructure. Through its REIT structure, Fermi offers investors exposure to AI infrastructure growth and long-term, large-scale and reliable energy development in a tax-efficient public vehicle.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: